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Summary 
CD30, a member of the tumor necrosis factor (TNF) 
receptor family, is expressed constitutlvely on the sur- 
face of the human T cell line ACH-2, which is chroni- 
cally infected with human lmmunodeficiency virus 
type-l (HIV)-1. We demonstrate that cross-linking 
CD30 with an anti-CD30-speclflc monoclonal antibody, 
which mimics the described biological activities of the 
CD30 llgand (CD30L), results In HIV expression. CD30 
cross-linking does not alter proliferation of ACH-2 cells 
and the induction of HIV expression is not mediated 
by endogenous TNFcf3. Furthermore, cross-linking of 
CD30 leads to NF-KS activation and enhanced HIV tran- 
scription. Thus, CD30-CD3OL interactions mediate the 
induction of HIV expression by a KS-dependent path- 
way that is independent of TNF. This mechanism may 
be important in the activation of HIV expression from 
latently infected CD4+ T cells, especially In lymphoid 
organs where cell to cell contact is conducive to recep- 
tor-ligand interactions. 
Introduction 
CD30 was originally identified by the monoclonal antibody 
(MAb) Ki-1 on neoplastic cells of Hodgkin’s lymphoma, as 
well as on a minor population of cells in normal lymphoid 
tissues (lymph node, tonsil, bone marrow, thymus, and 
spleen) (Schwab et al., 1982; Stein et al., 1982). CD30 
was subsequently found to be expressed on a subset of 
non-Hodgkin’s lymphomas that were predominantly of T 
cell origin and on virally transformed cell lines, such as 
human T lymphotropic virus (HTLV) I- and II-transformed 
T cells or Epstein-Barr virus (EBV)-transformed B cells 
(Stein et al., 1985; Froese et al., 1987). The expression 
of CD30 by normal immune competent cells was*rGn- 
forced by the fact that it could be induced by stimulating 
normal peripheral blood B and T lymphocytes with &phy- 
lococcus aureus Cowan I and phytohemagglutinin,‘.:re- 
spectively (Stein et al., 1985). Induction of CD30 pxp&s- 
sion is usually accompanied by the expression of other ., 
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activation-associated markers, such as HLA-DR and sub- 
units of the interleukin-2 (IL-2) receptor. Furthermore, it 
has been reported that CD30 is induced on CD4+Tlympho- 
cytes by alloactivation and, to a lesser degree, autoactiva- 
tion (Andreesen et al., 1984). T lymphocytes, predomi- 
nantly CD4+ cells derived exclusively from CD45RO’ 
memory cells, also express CD30 following activation with 
concanavalin A, ionomycin, antiCD2, and anti-CD3 (Ellis 
et al., 1993). Although the functions of CD30 remain 
largely unknown, the cDNAs encoding this molecule (Diir- 
kop et al., 1992) and its membrane-bound ligand (CD30L) 
(Smith et al., 1993) have been recently cloned. CD30 and 
CD30L belong to the tumor necrosis factor (TNF) receptor 
and the TNF ligand family, respectively. This emerging 
complementary receptor/ligand family includes several 
members involved in basic biological processes such as 
cellular proliferation and programmed cell death, as well 
as in immunologicfunctionssuch as immunoglobulin class 
switch and the development of lymph nodes (Smith et al., 
1994; Beutler and van Huffel, 1994). Among the members 
of these families, TNF has been shown to be a potent 
inducer of human immunodeficiency virus (HIV) expres- 
sion in several models (Folks et al., 1989; Israel et al., 
1989; Michihiko et al., 1989) and anti-Fas MAb has been 
shown to be cytocidal to HIV-infected cells without aug- 
menting viral replication (Kobayashi et al., 1990). With re- 
gard to the role of CD30 in HIV infection, the presence of 
high serum levels of soluble CD30 in the early phase of 
HIV infection has been recently reported to be a predictor 
of progression to AIDS, independent of other prognostic 
parameters (Pizzolo et al., 1994). However, no data are 
available concerning the direct involvement of CD30 in 
HIV replication. 
Results 
Constitutive Expression of CD30 on the Surface 
of ACH-2 and A.301 T Cell Lines 
To investigate the potential role of CD30 in HIV replication, 
we first demonstrated CD30 expression in the chronically 
HIV-infected T cell line ACH-2, which carries one copy of 
integrated provirus per cell and is characterized by low 
levels of virus production that can be up-regulated by 
TNFa (Clause et al., 1989). These cells constitutively ex- 
pressed CD30 on their surface, as well as other members 
of the TNF receptor family, such as CD27 and Fas (Table 
1). The A.301 cell line, the uninfected parental counterpart 
of ACH-2 cells, constitutively expressed similar levels of 
CD30, CD27, and Fas molecules (Table l), suggesting 
,that their expression is not altered by HIV infection. Both 
cell lines were negative for surface expression of CD30L. 
As previously described (Folks et al., 1988), CD4 is down- 
modulated in the chronically infected cell line ACH-2 com- 
pared with its uninfected counterpart A.301. Of interest is 
the down-modulation of CD25 the IL-2 receptor a chain, 
in ACHP compared with A.301 cells. 
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Table 1. Flow Cytofluorometric Analysis of Chronically Infected and 
Uninfected Cell Lines 
Surface 
Markers 
ACH-2 A.381 
(HIV-Infected) (Uninfected) 
(Percent) (Percent) 
CD28 83 89 
CD30 Ligand 3 1 
CD27 50 86 
Fas Ag 73 99 
CD3 54 80 
CD4 1 88 
CD25 0 75 
CD30 is involved in HIV Expression 
To determine whether CD30-CD3OL interaction could in- 
duce HIV expression from ACH-2 cells, mammalian CVl- 
EBNA cells transfected with the human CD3OL cDNA 
(CVl-CD30L) were used as a source of CD30L (Smith et 
al., 1993), whereas CVl cells transfected with vector alone 
(CVl -mock) were Used as control. Following transfection, 
cells were fixed (1% paraformaidehyde for 10 min), 
washed, and stained to determine the actual expression 
of surface CD30L (Figure 1A). Of the CVl-CD30L cells, 
24% were CD3OL positive, whereas none of the CVl- 
mock cells expressed CD3OL. When CVl-CWOL ceils 
were cocultured with ACH-2 ceils (in a 1:2 proportion), a 
moderate production of virus was observed over baseline 
(Figure 1 B), as measured by Mg%dependent reverse tran- 
scriptase (RT) activity in culture supernatants. Since 
cross-linking with MAb has been instrumental in eiucidat- 
ing the function of certain members of the TNF receptor 
family (Jabara et al., 1990; Banchereau et al., 1991; Es- 
pevik et al., 1990), we used a panel of MAbs directed 
against CD30 to test their effect on virus expression (Fig- 
ure 2A). Only two anti-CD3O-speciffc MAbs, M44 and M67, 
induced HIV expression. Both showed absolute specificity 
for human CD30 and induced cellular responses identical 
to those induced by the recombinant CD3OL, including 
enhancement of proliferation of anti-CD3activated T ceils 
and a panel of Hodgkin-derived cell lines as well as cyto- 
static effects on a panel of non-Hodgkin iymphoma cell 
lines(Smith et al., 1993; Grusset al. 1994). RTactivitywas 
induced by M44 and M67 in a concentration-dependent 
manner with levels comparable to those induced by solu- 
ble TNF (TNF6 shown in Figure 2A). Since the other anti- 
CD30 MAbs, Ki-1 (Schwab et al., 1962; Stein et al., 1962), 
Ber-H2 (Schwarting et al., 1969), and HRS-4 (Pfreund- 
schuh et al., 1966) were unable to induce HIV expression, 
CVl-mock CVlCD3OL 
Relative Fluorescence (channels) 
B. 600 r 
Figure 1. HIV Expression from CD3Cr+ ACHP 
Cells Is Induced by CVl-CD30L-Expressing 
Cells 
(A) Flow cytometric analysis was performed on 
CVl-mock and CVl-CD3oL fixed cells tc de 
termine surface expression of CD30L. Cells 
were reacted with the sotuble fusion protein 
CD3%Fc (Smith et al., 1993) that consists of 
the extracellular portion of CD30 linked to the 
Fc portion of human immunoglobulin 01 
(IgGl), followed by goat anti-human fluores- 
cein isothiocyanate-conjugated antibody 
(Jackson ImmunoResearch). Human IgGl 
(Sigma) was used as isotype control. The per- 
centage values shown in the diagrams are the 
straight integrations from two channels, 75- 
258 and 100-258. and the value of the sample 
from which the isotyfm has been subtracted 
(SUBTRACT). 
(B) Virfon production was detected in culture 
supernatants (day 2) by the RT activity assay 
described in Experimental Procedures. Solu- 
ble TNFa was used as a positive control. 
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Figure 2. HIV Expression Is Induced by Cross-Linking CD30 with Two 
Anti-CD30 Triggering MAbs, M44 and M67 
(A) FtTactivitywas detected inculturesupernatants(day5)fromACH-2 
cells cross-linked with a panel of anti-CD30 MAbs used at the concen- 
trations indicated. Maximal activity by cross-linking with M44 and M67 
was obtained with 100 pg/ml and lost with 1 pg/ml. Mouse lgG3 and 
IgGl (ICN Biomedical, Incorporated) were used as iaotypematched 
control antibodies for Ki-1 (Dako) and M44, MB7 (Immunex), Ber-HP 
(Dako), HRB-t (Amac, AbV Immunemsponse). respectively. Soluble 
TNFf3, which served as a positive control, was used at 100, 10, 1, and 
0.1 nglml. Resufts from one representative experiment of two that 
were performed independently are shown. 
(B) Flow cytometric analysis of ACH-2 cells stained with the panel of 
antiiD MAb reveals no differences in the percentage of positive 
cells stained by the HIV-inducers M44 and M67 and the noninducers 
Ber-HO. HRB-4, and Kl-1. The percentages shown are straight integra- 
tions from two channels, 76-266 and 100-266, and the value of the 
sample from which the isotype has been subtracted (SUBTRACT). 
MCH is the log mean channel of the positive peak. 
(C) Kinetics of HIV induction by anti-CD30 antibodies M44 (closed 
squares) and M67 (closed triangles) above constitutive virion produo 
tion (open circles). Baseline RT activhy of either mouse (m)lgGi- 
treated or untreated ACHP cells was usually the same. For kinetics 
experiments, ACH-2 cells were plated at an initial concentration of 
0.25 x W/ml; supernatants were harvested at the timepoints indi- 
cated and frozen at -70% until tested. Resuite from one representa- 
tive experiment of two that were performed independently are shown. 
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Figure 3. Cross-Linking of CD30 on ACH-2 Cells with M44 or M67 
Induces HIV Expression but Does Not Alter ACH-2 Proliferation 
(A) RT activity from supernatants harvested at day6 of culture of ACH-2 
cells treated with immobilized mlgG1, anti-CD30 M44 and M67. anti- 
CD27 M46, and the anti-Fas M3 (all at 10 ug/ml). 
(8) [3”]thymidine incorporation following treatment with the various 
MAbs described above. The same cells were pulsed with 0.5 uCi/well 
of PH)thymidine (DuPont New England Nuclear Products) for 16 hr, 
harvested by an automatic g&well plate harvester/washer, and the 
glass fiber filters were counted in a liquid scintillation counter. Results 
from one representative experiment of two that were independently 
performed are shown. 
we tested their ability to bind CD30 on ACH-2 cells (Figure 
26). Ki-1 , Ber-HP, and HRS-4 bound CD30 on the surface 
of ACH-2 cells as well as did M44 or M67, suggesting that 
they recognize epitopes of CD30 that are not involved in 
the events that lead to HIV production. In all subsequent 
experiments, M44 and M67 were used to cross-link CD30 
on ACHP cells to study the mechanisms involved in the 
induction of HIV expression. Studies on the kinetics of HIV 
expression revealed that HIV induction by M44 and M67 
was detectable after 24 hr, peaked around day 5, and 
lasted for several days of cell culture (Figure 2C). 
Lack of Proliferative Effects on ACH-2 Cells 
by HIV-Inducing MAbs M44 and M67 
Since M44 and M67 have been involved in the modulation 
of proliferation in different cellular systems (Smith et al., 
1993; Gruss et al., 1994), we analyzed whether HIV induc- 
tion by these MAbs was associated with an effect on prolif- 
eration of ACH-2 cells. No effect on thymidine incorpora- 
tion (Figure 38) was observed when HIV expression 
”  
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Figure 4. Autocrine Secretion of TNFa/5 Does Not Account for HIV 
Expression Induced by Cross-Linking of CD30 
RTactivity (day 2) was determined from ACH-2 cells treated with immo- 
bilized mlgG1, M44, and MB7 or with soluble TNFa or TNFf3 either 
alone (closed bar, medium) or in the presence of mouse anti-human 
(h)TNFa (striped bar) (5 ug/ml) (Olympus), mouse antihTNFf3 (shaded 
striped bar) (5 uglml) (Soehringer Mannheim) or soluble mlgG1 (stip- 
pled bar) (5 pg/ml) (ICN) as an isotype-matched control antibody. Re- 
suits from one representative experiment of two that were indepen- 
dently performed are shown. 
(Figure 3A) was induced by cross-linking of CD30 by M44 
or M67, as compared with the baseline thymidine incorpo- 
ration of ACH-2 cells cross-linked with an isotype-matched 
control antibody (Figure 38). The lack of proliferative ef- 
fects of M44 and M67 was confirmed at different time- 
points by kinetic studies (data not shown). We also tested 
two other MAbs, M46 and M3, which specifically recognize 
two other members of the TNF receptor family, CD27 and 
Fas, respectively. Anti-CD27 (M46) showed no effect on 
HIV expression (Figure 3A) or cell proliferation (Figure 38). 
Anti-Fas (M3) resulted in a decrease of baseline HIV pro- 
duction (Figure 3A) that correlated with a potent inhibition 
of proliferation (Figure 38) and a rapid and dramatic killing 
of ACH-2 cells, confirming the well-described apoptosis- 
inducing function of Fas on susceptible cell lines. 
HIV Induction by Anti-CD30 MAb M44 and M67 Is 
Not Mediated Through Endogenous 
TNF Secretion 
We have previously shown that stimulation of ACH-2 cells 
with phorbol myristate acetate (PMA) induced HIV expres- 
sion, in part through the autocrine secretion of TNFa (Poli 
et al., 1990). We therefore determined whether autocrine 
secretion of TNF was also responsible for virus production 
induced by CD30 cross-linking. Blocking antibodies di- 
rected against TNFa or TNF6 abrogated HIV production 
induced by their respective cytokine, but had no effect on 
the RT activity induced by M44 or M67 (Figure 4), indicat- 
ing that cross-linking of CD30 on ACHP cells leads tovirus 
expression independent of endogenous secretion of either 
TNFa or TNF6. 
Accumulation of HIV Messages Is Induced 
by Cross-Linking of CD30 
In addition to detectingvirions released in culture superna- 
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Figure 5. Accumulation of HIV Steady-State mRNAs Is Induced by 
Cross-Linking of CD30 
Northern blot analysis was performed on total RNA from 10’ ACH-2 
cells either unstimulated (72 hr. lane I), incubated with mlgG1 (72 hr, 
lane 2) stimulated with M44 (72 hr, lane 3) TNFa (48 hr, lane 4). or 
TNF5 (45 hr, lane 5). The same filter wasstripped and rehybridized with 
a 5-actin probe, as a control (bottom). Similar results were obtained in 
a second experiment that was independently performed. 
tants (through the activity of the enzyme RT), we per- 
formed Northern blot analyses to detect the induction of 
HIV at earlier steps in its life cycle. Cross-linking of CD30 
by M44 resulted in accumulation of all three species of HIV 
messages (mRNAs) (Figure 5) suggesting that it induced 
transcription, as previously described for TNFa (Osborn 
et al., 1989; Duh et al., 1989). Unstimulated ACH-2 cells 
(Figure 5, lane 1) as well as ACH-2 cells treated with iso- 
type-matched control antibody (lane 2) show detectable 
levels of fully spliced 2 kb mRNA of HIV regulatory genes 
tat, nef, and rev, and 4.5kb mRNA of envelope. Similar 
to TNFa (Figure 5, lane 4) and TNF8 (lane 5) CD30 cross- 
linking (lane 3) enhanced the 2 and 4.5 kb mRNAs and 
induced the 9 kb mRNA coding for gag-pol structural 
protein. 
CD30 Cross-Linking Leads to the Activation 
of NF-KS 
TNFa has been shown to induce HIV transcription through 
activation of the cellular transcription factor NF-KB that 
binds to KB sites present in the HIV long terminal repeat 
(LTR)(Osborn et al., 1989; Duh etal., 1989). We performed 
electrophoretic mobility shift assays (EMSAs), which dem- 
onstrated that CD30 cross-linking induced NF-KB binding 
(Figure 8A). Unstimulated cells (Figure 8A, lane 1) present 
a constitutive NF-KB-specific band (open arrowhead). 
TNFa (Figure 6A, lane 4) induces an additional discrete 
upper band (closed arrowhead), which is abrogated by the 
addition of anti-TNFa antibody to the cell culture (lane 5) 
whereas M44 (lane 2) induces a similar migrating upper 
band (closed arrowhead), which is unaffected by anti- 
TNFa antibody (lane 3) indicating that NF-KB induction 
by CD30 cross-linking, as well as HIV induction, is inde- 
pendent of autocrine TNFa. Figure 6A, lane 8 shows probe 
alone without cell extracts. Both bands are NF-KB specific 
in that they are abrogated by a lOO-fold excess of cold 
NF-KB probe (data not shown). Since the NF-KB family is 
comprised of several members (Siebenlist et al., 1994; 
Bauerle and Henkel, 1994; Grilli et al., 1993) that can di- 
merize resulting in the formation of different complexes, 
we further investigated which proteins were contained in 
the NF-xB-specific bands of stimulated ACH-2 cells (Fig- 
ures SB-SC). For this purpose, EMSAs were performed 
with the extracts of MM-stimulated (Figure 6B) and TNFa- 
stimulated(Figure6C)ACH-2cellsin theabsence(Figures 
6B-6C, lanes 1) or presence of antibodies that specifically 
recognize the following membersof the NF-KB family: ~50, 
~52, ~65, oReI, and Rel-8 (Figures 6&6C, lanes 2-8). 
The lower band (open arrowhead), which was also present 
constitutively in unstimulated cells (Figure 8A, lane l), was 
supershifted only by anti-p50 antibody (Figures 6B and 
6C, lane 2, lower closed circle), indicating that it contained 
~50 homodimers. The upper band (closed arrowhead), 
which was induced only upon stimulation, was super- 
shifted by p50 antibody (Figures 6B and 8C, lane 2, lower 
closed circle) and also by p65 antibody (Figures 6B and 
6C, lane 4, upper closed circle), demonstrating that it con- 
tained transactivating ~501~65 heterodimers. Therefore, 
we have identified the specific NF-KB proteins present in 
unstimulated and stimulated ACH-2 cells and have dem- 
onstrated that the same complexes are induced by stimu- 
lation either with TNFa or CD30 cross-linking. 
KB Sites in the LTR Are Required for HIV 
Transcription Induced by CD30 Cross-Linking 
Because NF-KB activation is necessary for the induction 
of HIV transcription by TNFa in ACH-2 cells (Osborn et 
al., 1989; Duh et al., 1989) we investigated whether the 
same was true for induction by CD30 cross-linking. ACH-2 
cells were transiently transfected either with an HIV LTR 
construct linked to the reporter gene chloramphenicol ace- 
tyltransferase (CAT) (IBI-CAT) or with its respective plas- 
mid in which the KB sites were deleted (NFA-CAT) (Figure 
7). Cross-linking of CD30 by M44 (or M67, data not shown) 
resulted in the induction of CAT activity (Figure 7A) when 
the ceils were transfected with the HIV LTR-CATwild-type 
construct, confirming the transcriptional effect suggested 
by the Northern blot analysis (see Figure 5). The levels of 
LTR transactivation induced by TNFa and CD30 cross- 
linking were comparable (Figure 7A), although lower than 
those induced by nonphysiologic HIV inducers, such as 
PMA and sodium butyrate (NaB) (Figure 7B). Similar to 
TNFa (and TNF8, data not shown), CAT activity was not 
induced by CD30 cross-linking when the cells were 
transfected with the deleted KB construct (Figure 7C), 
demonstrating thattransactivation of the HIV LTR byCD30 
cross-linking requires the presence of NF-KB sequences. 
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Figure 6. Cross-Linking of CD90 Induces NF-KB Activation 
(A) CD90 triggering induces NF-KB binding independent of endoge- 
nous TNFa. EMSA was performed with whole cell extracts (2 hr) made 
from 10’ ACH-2 cells treated with mlgG1 (100 mg/ml) (lane 1). M44 
alone (100 ug/ml) (lane 2) or in the presence of soluble anti-TNFa (5 
&ml) (Olympus) (lane 3) TNFa alone (lane 4) or in the presence of 
anti-TNFa (lane 5). Unstimulated ACH-2 cells display only the constitu- 
tive lower band (data not shown), similar to mlgGl-treated ACH-2 cells 
(lane 1). M44 at the lower concentrations of 10 ug/ml and M67 also 
induced NF-KS activation (data not shown). Comparable amounts of 
cell extracts (12-l 4 ftg) were loaded in each lane. 
(B-C) Supershift assay with the same extracts (2 hr) of the h&M- and 
TNFa-stimulated ACH-2 cells, respectively, is shown in (A). Lane 1 
shows the bands present in extracts from M44- and TNFa-stimulated 
ACH-2 cells in the absence of antibody. Lanes 2-6 show the bands 
from the extracts of M44- and TNFa-stimulated ACH-2 cells incubated 
with ~50. ~52. ~65, c-Rel, and Rel-b antibody, respectively. The open 
arrowhead points to the constitutive NF-K&specific lower bands. The 
closed arrowhead points to the upper bands induced upon stimulation 
by M44 and TNFa. The lower and upper circles indicate the bands 
resultingfrom thesupershiftwith thep5Oand thep65antibody, respec- 
tively. The arrow on the right of Figure 6 B/C indicates a nonspecific 
band of the supershift assay present in all lanes where antibodies 
were incubated with the cell extracts. 
CAT activity could be induced from the deleted KB con- 
struct by NaB (Figure 7C), a partial NF-xB-independent 
stimulus of HIV transcription (Antoni et al., 1994). Similar 
CAT activity results were obtained with another wild-type 
HIV LTR construct (pU3R-III) and its respective deleted 
KB construct (Bressler et al., 1991) (data not shown). 
Dlscussion 
CD30 (Ki-1) has been a useful marker for the diagnosis 
of Hodgkin’s lymphoma, although it is also expressed on 
a small population of cells in normal lymphoid tissues 
(Schwab et al., 1982; Stein et al., 1982). Biochemical char- 
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Figure 7. HIV LTR Transactivation Is Induced by CD30 Cross-Linking 
and Requires the Presence of KB Sites 
(A) HIV LTR transactivation is induced by cross-linking of CD30 by 
M44 (and M67 antibody, data not shown), with levels comparable to 
those induced by soluble TNFa (and TNFf3, data not shown). 
(6) HIV LTR transactivation is also strongly induced by nonphysiologic 
stimuli, such as PMA and NaB. 
(C) ACHP cells transfected with a construct of HIV lacking the KB 
sites (NFA-CAT) are unresponsive to TNFa stimulation and CD30 
cross-linking by M44 (and M67, data not shown). One representative 
experiment of two that were independently performed is shown. Fold 
induction of CAT activity was calculated by dividing the counts per 
minute (cpm) of the test samples by the cpm of the unstimulated ACH-2 
cell sample for each set of transfected cells. 
acterization of CD30 (Fro&se et al., 1987; Nawrocki et al., 
1988; Hansen et al., 1990) indicated a regulatory role of 
this molecule in lymphoid activation. The molecular clon- 
ing of the human CD30 gene (Durkop et al., 1992) and 
establishment of CD30 as a member of the TNF receptor 
superfamily (Smith et al., 1994; Beutler and van Huffel, 
1994), which is comprised of cellular and viral proteins 
involved in activation, costimulation, and death events, 
has further broadened the interest for this molecule. 
There are two reports that associate CD30 with HIV in- 
fection: the first indicates high levels of soluble CD30 in 
early phase disease as an independent predictor of pro- 
gression to AIDS (Pizzolo et al., 1994), and the second 
demonstrates that a large number of CD8+ CD30+ T cell 
clones that produce type 2 cytokines can be derived from 
the peripheral blood mononuclear cells of HIV-infected 
individuals (Manetti et al., 1994). However, neither study 
indicates a role for CD30 in the induction of HIV replication. 
In the present study, we have directly addressed this 
issue and have demonstrated that cross-linking certain 
epitopes of CD30 on a chronically infected T cell line leads 
to HIV expression as measured by release of virions in 
culture supernatants, accumulation of HIV mRNAs, and 
activation of the HIV LTR. Furthermore, we have shown 
that CD30 cross-linking results in NF-KB activation and 
that the KB sites present in the HIV LTR are required for 
HIV transcription. 
HIV infection is characterized by a variably prolonged 
period of clinical latency following primary infection (Fauci, 
1993). However, as HIV disease progresses, there is a 
destruction of the microenvironment of lymphoid tissue, 
high levels of viremia are easily detected in peripheral 
blood, and large numbers of cells actively produce virus. 
It is important to understand the mechanisms underlying 
the activation of the large pool of latently infected cells 
(Embretson et al., 1993) and the progressive destruction of 
lymphoid tissue (Pantaleo et al., 1993). Cytokines, soluble 
mediators of intercellular communications, play a critical 
role in the regulation of HIV expression from latently in- 
fected cells (Poli and Fauci, 1993). Less well documented, 
but potentially equally important, is the role that cell to cell 
contact may play in this process. 
The present study suggests a model in which a latently 
infected CD4+ CD30+ T cell comes into close contact with 
an activated monocyte or T cell expressing CD30L, ra 
sulting in active production of HIV and spread of infection. 
In addition to the autocrine and paracrine induction of HIV 
expression by endogenous cytokines (Poli et al., 1990; 
Fauci, 1993), this potential mechanism of induction of virus 
expression from latently infected cells by direct cellular 
interaction may play an important role in the pathogenesis 
of HIV disease. 
Finally, a considerable effort has been devoted to the 
therapeutic strategy of blocking TNFa (Fauci, 1993; Les- 
slauer et al., 1991; Bertini et al., 1993; Mohler et al., 1993; 
Sampaio et al., 1992; Streiter et al., 1988; Dezube et al., 
1990; Bianco et al., 1991; Holler et al., 1990; Dezube et 
al., 1993; Mohleret al., 1994; Gearinget al., 1994; McGee- 
han et al., 1994) for the purposes of obviating its catabolic 
effects as well as its ability to induce HIV expression. Ap 
preciation of the potential for the up-regulation of HIV ex- 
pression by interaction of CD30 with CD30L through cellu- 
lar contact within the microenvironment of lymphoid tissue 
should prompt the consideration of therapeutic strategies 
aimed at inhibiting this process. 
Expertmental Procedures 
Cell Culture and Cross-Llnldng Condltlons 
Mycoplasma-free ACH-2 cells were maintained in RPM1 1640 medium 
containing 10% fetal calf serum and plated at a concentration of 
0.5 x W/ml, unless otherwise indicated. Soluble TNFa (2 @ml), 
TNFg (10 nglml; Boehringer Mannheim), PMA (10 r&f), and NaB (1 
mM; Sigma) were added directly to the cultures at the onset of the 
experiments. 
For cross-linking, the MAbs were diluted in 1 x phosphate-buffered 
saline (PBS) to a concentration of 10 &ml (unless otherwise speci- 
fied), immobilized to polystyrene tissue culture plates/flasks overnight 
at 4OC, and washed three times with cold PBS prior to addition of the 
cells. For all experiments, M44 and M87 were used at a concentration 
of 10 pg/ml, unless otherwise indicated. 
Phenotyplc Analyele 
Common indirect immunofluorescence procedures were followed. 
Usually, 2 x 106 cells were stained with a primary mouse antibody 
for 30 min at 4OC, washed twice with cold PBS, incubated with a 
secondary goat anti-mouse fluorescein isothiocyanate-conjugated an- 
tibody (Jackson ImmunoResearch) for 30 mln at 4OC, washed twice 
with cold PBS, and fixed with formaldehyde 1% prior to flow cytofluoro- 
metric analysis on an Epic profile instrument. Monoclonal anti-CD30 
(M44 and M67). anti-CD27 (MM), anti-Fas (M3), and soluble fusion 
protein CD30 Fc (for the detection of surface CD3OL expression) were 
obtained from Immunex, whereas antiCD3, anti-CD4, and anti-CD25 
were obtained from Becton Dickinson. 
The assay was performed using a modified microtiter version (Biswas 
et al., 1992) of the RT activity assay described previously (Willey et 
al., 1988). Cultures were carried out in duplicate or triplicate and the 
variability of replicate cultures was always <15%. 
Northern Blol Analyela 
The assay was performed as previously described (Biswas et al., 1994) 
with total RNA extracted from ACH-2 cells. 
EMSA 
Whole cell extracts were prepared as described (Franzoso et al., 1994). 
The NF-KB oligonucleotide probe and the assay have been previously 
reported (Bressler et al., 1991). as well as the antibodies used in the 
supershift analysis (Franzoso et al., 1992; Bours et al., 1993). 
CAT Aeeey 
The constructs used and the procedure for transient transfection (a 
modified DEAE-Dextran procedure) (Bressler et al., 1991) as well as 
the CAT assay (Bressler et al., 1993; Neumann et al., 1987) have been 
previously described. ACH-2 cells (lq were transfected with each 
construct (20 kg), divided into several aliquots, and were either left 
untreated or treated for 48 hr with anti-CD30 antibody, TNFa, PMA, 
NaB. Each sample was standardized for total protein content. 
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